Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical)

Product Name :
Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical)

Search keywords :
Trastuzumab

drugId :
null

Target Vo:
Receptor protein-tyrosine kinase erbB-2

Target Vo Short Name :
HER2

Moa_Name:
Receptor protein-tyrosine kinase erbB-2 antagonists

First Approval Country :
Mainland China

First Approval Date Filter:
2023

Origin Company_Name :
Zhejiang Hisun Pharmaceutical Co Ltd

Active Company_Name :
Hisun Biopharmaceutical Co Ltd

Active Indication_Name:
Breast Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
NEDD8 Antibody
eIF1A Antibody
DDIT3 Antibody: DDIT3 Antibody is an unconjugated, approximately 19 kDa, rabbit-derived, anti-DDIT3 polyclonal antibody. DDIT3 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, rabbit, sheep background without labeling.

Author: Betaine hydrochloride

Related Posts